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To be able to describe the differences between the normal and tumor tissues of gastric cancer at a molecular level would be essential in the
study of the disease. We investigated the gene expression pattern in the two types of tissues from gastric cancer by performing expression profiling
of 86 tissues on 17K complementary DNA microarrays. To select for the differentially expressed genes, class prediction algorithm was employed.
For predictor selection, samples were first divided into a training (n=58), and a test set (n=28). A group of 894 genes was selected by a t-test in a
training set, which was used for cross-validation in the training set and class (normal or tumor) prediction in the test set. Smaller groups of 894
genes were individually tested for their ability to correctly predict the normal or tumor samples based on gene expression pattern. The expression
ratios of the 5 genes chosen from microarray data can be validated by real time RT-PCR over 6 tissue samples, resulting in a high level of
correlation, individually or combined. When a representative predictor set of 92 genes was examined, pathways of ‘focal adhesion’ (with gene
components of THBS2, PDGFD, MAPK1, COL1A2, COL6A3), ‘ECM-receptor interaction’ pathway (THBS2, COL1A2, COL6A3, FN1) and
‘TGF-beta signaling’ (THBS2, MAPK1, INHBA) represent some of the main differences between normal and tumor of gastric cancer at a
molecular level.
© 2007 Elsevier B.V. All rights reserved.Keywords: cDNA microarray; Gene expression; Gastric cancer; Real-time RT-PCR1. Introduction
Gastric cancer is the second-most-common cause of cancer-
related mortalities [1]. Traditionally, clinico-pathological fac-
tors have been used most frequently and are still important in
assessing the prognosis of gastric cancer, albeit with limited
applicability [2]. Therefore, the need exists for more objective
molecular approaches in the assessment of gastric carcinogen-
esis and prognosis. Recent applications of genomic tools have⁎ Corresponding author. Department of Internal Medicine, Yonsei University
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doi:10.1016/j.bbadis.2007.05.005produced a vast amount of information on the differential gene
expression patterns related with gastric cancer. These include
oligonucleotide or cDNA microarray-based gene expression
profiling of the gastric carcinoma cell lines [3], identification of
the gastric cancer metastasis-related genes [4,5] and the
selection of the differentially expressed gene sets that can
distinguish between normal and cancerous gastric tissues, or
between the subtypes of gastric cancer [6–10].
Class prediction is a powerful statistical tool that has been
successfully applied to the microarray-based cancer genomics
research. It is a process of assigning a particular test sample to
among the pre-determined classes based on the similarity to
expression profiles of samples in the training set. In a systematic
approach to cancer classification and prediction, Golub et al.
Table 1
Summary of cross-validation in the training set and prediction in the test set
Genes k nearest neighbor-based class prediction
Predictor Prediction Gene selection algorithm a
genes b strength Signal-to-noise Fisher's exact test
Cross-
validation
(%)
Prediction
(%)
Cross-
validation
(%)
Prediction
(%)
894 – c 100 96.4 100 96.4
358 20.5 100 96.4 100 96.4
312 21.7 100 96.4 100 96.4
256 23.6 100 96.4 100 96.4
198 25.4 100 96.4 100 96.4
139 27.3 100 96.4 100 96.4
92 29.4 100 96.4 100 96.4
66 31.2 100 96.4 100 96.4
34 34.5 100 96.4 100 96.4
10 37.9 100 96.4 100 96.4
a The specific numbers of predictor genes were determined based on the
prediction strength, and that number of genes was put into the gene selection
algorithms of signal-to-noise or Fisher's exact test function to perform the cross-
validation or prediction in the GeneSpring.
b The gene numbers are accumulative from the highest prediction strength.
For example, the 34 genes with a prediction strength of 34.5, contain 10 genes
with prediction strength of 37.9 and 24 additional genes.
c Between gene numbers of 358 and 894, there were many groups of
prediction strengths and not all of them are shown here.
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tion from a training set could be used to select a subset of genes
(class predictor), which can classify the two different types of
acute leukemias [11]. Tay et al. also used a similar system to
accurately predict the subtype of an unknown gastric tumor
sample [9]. In this report, using 86 gastric tissues that were
allocated into a training set and a test set, the predictor gene sets
were selected and the classifier was developed in the training set
and the efficiency in the discrimination of normal versus tumor
tissues was measured in the test set. The selected genes will help
to explain the nature of molecular changes between normal and
tumor tissues of gastric cancer.
2. Materials and methods
2.1. Tissue samples and RNA extraction
All experiments using the patient tissues were performed with approval from
the Internal Review Board of Yonsei University College of Medicine. Tissues
from the patients who underwent surgery at the Yonsei University College of
Medicine during 1997–1999 were used. Tissues that contained at least 70%
tumor content were used. The tissue samples (n=86) were divided into a training
set of 29 pairs (29 normal tissues and 29 matching tumor tissues, n=58) and a
test set of 28 samples (7 pairs, 8 non-paired normal tissues and 6 non-paired
tumor tissues). ‘Normal’ refers to histologically normal gastric tissues and
‘tumor’ refers to gastric adenocarcinomas. The total RNAwas extracted from the
homogenized tissues using TRIzol (Invitrogen, Carlsberg, CA) reagent
according to the manufacturer's protocol, and was further purified using
RNeasy Mini Kit (Qiagen, Valencia, CA).
2.2. cDNA microarray and hybridization
Gene expression profilings were performed on cDNA microarrays contain-
ing 17,000 human probes. These microarrays have been successfully used in a
number of projects before [12–17], producing reliable results. Polymerase chain
reaction (PCR) products from Ultimate™ ORF Clones (Resgen/Invitrogen,
Carlsbad, CA) were used to manufacture human 17K cDNA microarrays
(GenomicTree, Daejeon, Korea). OmniGridTM Microarrayer (GeneMachines,
Inc., San Carlos, CA) was used for printing PCR products onto a silanized glass
slide surface (CMT-GAPSTM, Corning, Charlotte, NC). These 17,000 genes
represent sequence-verified clones by the manufacturer. Of these, about 10,000
were function-annotated clones and the rest were CGAP (Cancer Genome
Anatomy Project, NCI, USA) clones. The microarray hybridization was
performed in an indirect-design; each of the cDNA targets generated from
tissue total RNAs (Cy5-labeled) were competitively hybridized with cDNAs
generated from the common reference RNA pool (Cy3-labeled) in each of the
hybridization following a published protocols [18]. Common reference RNA,
which is biologically irrelevant to the samples being analyzed and only functions
to provide a denominator in ratios in cDNA microarrays, was prepared by
pooling equivalent amount of total RNAs from the following cell lines; AGS,
MDA-MB231, HCT 116, SK-HEP-1, A-549, HL-60, MOLT-4, HeLa, Caki-2,
U-87MG, SK-MEL-2 and Capan-2 [12]. Hybridized slides were washed and
then scanned using a Gene Pix 4000B laser scanner (Axon Instrument Inc,
Union City, CA). The data were saved in a Gene Pix Result (GPR) format.
2.3. Microarray data analysis
Raw data normalization, gene filtering, classifier gene selection, cross-
validation for the training set and the class prediction for the test and
independent sets were performed using GeneSpring 7.0 software (Silicon
Genetics, Redwood City, CA). The raw data were print-tip normalized using the
lowess function prior to gene filtering. Poor signals (signals not more than 1.5-
fold higher than background signal in either of the Cy3 or Cy5) were removed
from further analysis. Genes with Cy5/Cy3 ratios missing in at least one sample
were also removed. The reliable genes were obtained by filtering the data bycontrol strength-based elimination of the genes with a low control spot signal
using the ‘cross-gene error model’ function in Gene Spring (12,891 genes
remaining). A paired t-test was performed to select the differentially expressed
genes between normal and tumor tissue groups (894 genes, pb0.05). The
Westfall and Young permutation-based multiple testing correction of the p-
values was used to minimize the occurrence of false positives. Two class
prediction functions, k-nearest neighbor classification rule (k=14) and support
vector machine, were used for the prediction. To accomplish this, 894 genes
were subjected to cross-validation in the training set. This procedure generated
the prediction strengths (negative natural log of the p-value) for all of the 894
genes. The prediction strengths were evaluated for all genes on the selected gene
list using the samples and their gene expression data in the training set. All genes
were evaluated independently and ranked according to their power to
discriminate each class from the others using the information from that gene
alone. The 894 genes were then grouped based on the prediction strengths. In
this system, each gene calculates the probability of obtaining an observed
number of samples from each class (normal or tumor) above and below the
“idealized expression pattern” [11]. Instead of using random small numbers,
gene numbers based on the prediction strength were used as selection criteria for
a smaller number of genes from the 894 genes (Table 1). A full dataset of gene
expression ratios of 17,000 genes and 86 patient tissues can be accessed at the
web site of Cancer Metastasis Research Center (http://cmrc.yonsei.ac.kr/) with
permission. Probes with unique Genbank accession numbers were counted as
individual genes for current analysis.
2.4. Quantitative real-time reverse transcription-PCR
To confirm the microarray data with real-time RT-PCR, 3 pairs of gastric
tissues (3 normal and 3 tumor) from the training set were randomly chosen and
their expression levels were measured. The reaction was carried out in a total
volume of 20 μl, which included 10 μl of QuantiTect SYBR Green PCRmixture
containing 2.5 mM MgCl2 (Qiagen, CA), 2 μl of the cDNA and 20 pmol of
oligonucleotide primers. PCR was performed at 95 °C for 15 min in order to
activate the HotstarTaq DNA polymerase, and then for 35 cycles of
amplification at 95 °C for 20s, 50 °C for 30s, 72 °C for 45 s on a Rotor Gene
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amplified fluorescence signal in each specimen was measured at the late
extension step of each cycle. In order to quantify the signals from each gene,
we used 10-fold serially diluted human genomic DNA as a control. The
following oligonucleotide primers were used; 5′-gatacgacactgtccaggtt-3′
(forward) and 5′-ccagttcagacttccagtgt-3′ (reverse) for PGA5, 5′-tctgttcaaaa-
catgttcca-3′ and 5′-tgtggtaaataagattgggg-3′ for LIPF, 5′-acgaggacatagatgac-
gac-3′ and 5′-tttacaaatatcaccccgtc-3′ for THBS2, 5′-agctcacctatttgcatcat-3′
and 5′-ctctgtaattgcgacatgaa-3′ for REP15, 5′-gagaggggctgggcta-3′ and 5′-
attcaaacaacagagccg-3′ for PARP10, and 5′-gggaattcaaaactggaacggtgaagg-3′
and 5′-ggaagcttatcaaagtcctcggccaca-3′ for β-Actin.
3. Results
3.1. Selection of the class predictors, cross-validation in the
training set and tissue type prediction in the test set
The t-test between the tissue types (normal or tumor) in the
training set resulted in the selection of 894 genes out of 12,891Fig. 1. Expression pattern of predictor gene set. The expression ratios for the 92 genes
result was shown as a heatmap. An enlarged view of the sample clustering is shown
followed by N (normal) or T (tumor). A scale bar representing the relationship betw
information including Genbank accession numbers, gene names and ratios for the 9at adjusted pb0.05. The cross-validation with the 894 genes
showed that the tissue types of all of the 58 samples in the
training set were correctly predicted (Table 1). The same set of
894 genes was then used to predict the tissue types in the test
set. Twenty-seven of the 28 samples (96.4%) in the test set were
correctly predicted. The cross-validation and prediction process
resulted in the ranking of the 894 genes according to the
prediction strength (a negative natural log of p-values, Materials
and methods) of each gene. The subsets of the 894 genes were
then formed based on the prediction strength (Table 1), and
were used for cross-validation in the training set and for
prediction in the test set. The prediction efficiency for the test
set remained the same at 96.4% from 894 genes down to 10
genes. In order to visualize the relative expression pattern of the
predictor genes in both tissue types, a two-way hierarchical
clustering of the representative set of 92 genes in the training set
was performed (Fig. 1). The detailed information about the 92in the 58 training set were subjected to a two-way hierarchical clustering and the
vertically, in the middle, each tissue sample being labeled with a unique number
een the color intensity and gene expression log ratios is also shown. A detailed
2 genes is in Table 2.
Table 2
Information of the predictor set of 92 genes
GB accession number Name Symbol Cytoband N T T/N
AI925826 Inhibin, beta A INHBA 7p15 0.17 3.37 19.82
H38240 Thrombospondin 2 THBS2 6q27 0.88 12.56 14.27
AA487193 Secreted frizzled-related protein 4 SFRP4 7p14.1 1.02 11.84 11.61
AI828306 Collagen, type X, alpha 1 COL10A1 6q21 1.75 15.65 8.94
AA953560 Est Est 0.18 1.58 8.78
AA496283 Thy-1 cell surface antigen THY1 11q22.3 0.89 5.77 6.48
AA405569 Fibroblast activation protein, alpha FAP 2q23 0.86 5.21 6.06
AA490172 Collagen, type I, alpha 2 COL1A2 7q22.1 2.86 17 5.94
R62603 Collagen, type VI, alpha 3 COL6A3 2q37 0.3 1.75 5.83
AW075162 TIMP metallopeptidase inhibitor 1 TIMP1 Xp11.3 0.77 3.53 4.58
AI057267 Thy-1 cell surface antigen THY1 11q22.3 1.2 5.37 4.48
AA683077 Mitogen-activated protein kinase 1 MAPK1 22q11.2 0.66 2.91 4.41
AA857098 Transcribed locus Est 0.71 2.9 4.08
R71093 Serpin peptidase inhibitor, clade H, 1 SERPINH1 11q13.5 0.43 1.68 3.91
H95960 Secreted protein, acidic, cysteine-rich SPARC 5q31.3 0.7 2.72 3.89
N33214 Matrix metallopeptidase 14 MMP14 14q11 1.07 3.63 3.39
T96082 RAB31, member RAS oncogene family RAB31 18p11.3 0.48 1.36 2.83
AI814383 Cathepsin L2 CTSL2 9q22.2 0.51 1.44 2.82
AA885869 ATPase, Class VI, type 11A ATP11A 13q34 0.5 1.36 2.72
W73874 Cathepsin L1 CTSL1 9q21 0.45 1.22 2.71
R56774 Bone morphogenetic protein 1 BMP1 8p21 0.53 1.41 2.66
AA862371 Interferon induced transmembrane protein 2 (1–8D) IFITM2 11p15.5 0.92 2.31 2.51
AA485151 Heat shock 105 kDa/110 kDa protein 1 HSPH1 13q12.3 0.52 1.3 2.5
AA459305 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 PLOD3 7q22 0.48 1.17 2.44
AA446259 Protein tyrosine phosphatase, non-receptor type 12 PTPN12 7q11.23 0.51 1.19 2.33
AI739206 Ephrin-A4 EFNA4 1q21 0.7 1.63 2.33
AI271909 Transcribed locus Est 2.08 1.24 0.6
AA873577 ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit ATP5O 21q22.1 1.59 0.81 0.51
AA598865 Superkiller viralicidic activity 2-like 2 SKIV2L2 5q11.2 1.21 0.59 0.49
AA280832 UDP-galactose-4-epimerase GALE 1p36 2.63 1.27 0.48
AI884731 Wingless-type MMTV integration site family, member 10B WNT10B 12q13 1.25 0.59 0.47
AA047567 Progesterone receptor membrane component 2 PGRMC2 4q26 1.23 0.57 0.46
AA455261 Chromobox homolog 7 CBX7 22q13.1 3.14 1.44 0.46
AA629687 Nuclear factor (erythroid-derived 2)-like 2 NFE2L2 2q31 1.85 0.81 0.44
AI951084 Diacylglycerol kinase, delta 130 kDa DGKD 2q37.1 2.02 0.88 0.44
AI418638 Chromosome 4 open reading frame 34 C4orf34 4p14 3.22 1.39 0.43
AI675465 Homocysteine-inducible, endoplasmic reticulum stress-inducible,
ubiquitin-like domain member 1
HERPUD1 16q12.2 2.2 0.91 0.41
AI768615 Immature colon carcinoma transcript 1 ICT1 17q25.1 1.29 0.53 0.41
AA521345 BTB (POZ) domain containing 2 BTBD2 19p13.3 3.18 1.28 0.4
AI924634 Involucrin IVL 1q21 1.33 0.53 0.4
AA455925 Four and a half LIM domains 1 FHL1 Xq26 1.87 0.74 0.4
AA279980 Basic helix–loop–helix domain containing, class B, 3 BHLHB3 12p11.23 2.65 1.03 0.39
AA932696 Family with sequence similarity 107, member A FAM107A 3p21.1 4.16 1.59 0.38
AI350508 Family with sequence similarity 107, member A FAM107A 3p21.1 4.44 1.65 0.37
AW071052 Small glutamine-rich tetratricopeptide repeat (TPR)-containing, alpha SGTA 19p13 2.74 1.01 0.37
AA282063 Polymerase (RNA) III (DNA directed) polypeptide C (62 kDa) POLR3C 1q21.1 1.81 0.64 0.35
AW058344 Zinc finger and BTB domain containing 48 ZBTB48 1p36.3 2.72 0.94 0.35
AI923970 Cathepsin F CTSF 11q13 3.8 1.26 0.33
AA488996 Platelet derived growth factor D PDGFD 11q22.3 1.32 0.43 0.33
AA490497 Ubiquitin-like 3 UBL3 13q12 5.44 1.76 0.32
AA521439 Synaptotagmin-like 2 SYTL2 11q14 6.25 1.93 0.31
AI147534 Glutathione peroxidase 3 (plasma) GPX3 5q23 5.62 1.63 0.29
AI032392 RAB27A, member RAS oncogene family RAB27A 15q15 4.24 1.2 0.28
AA436401 Family with sequence similarity 107, member A FAM107A 3p21.1 8.06 2.11 0.26
AW008766 Kruppel-like factor 4 (gut) KLF4 9q31 8.42 2.18 0.26
AI933187 Protein inhibitor of activated STAT, 4 PIAS4 19p13.3 1.51 0.39 0.26
AA486324 Proteasome (prosome, macropain) activator subunit 3 PSME3 17q21 5.19 1.3 0.25
AA069024 Aldehyde dehydrogenase 3 family, memberA1 ALDH3A1 17p11.2 2.1 0.51 0.24
AA281635 Interleukin 24 IL24 1q32 6.03 1.46 0.24
H45668 Kruppel-like factor 4 (gut) KLF4 9q31 11.99 2.78 0.23
AA931491 Hypothetical protein LOC143381 LOC143381 10q26.11 2.08 0.47 0.23
AA521228 3-hydroxyisobutyryl-Coenzyme A hydrolase HIBCH 2q32.2 4.15 0.9 0.22
AI674972 Progastricsin (pepsinogen C) PGC 6p21.3 99.85 21.61 0.22
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Table 2 (continued)
GB accession number Name Symbol Cytoband N T T/N
AW009769 Trefoil factor 1 TFF1 21q22.3 96.35 20.2 0.21
AI302661 Transcribed locus Est 0.7 0.14 0.2
AI333599 Gastrokine 1 GKN1 2p14 99.84 18.13 0.18
H94487 Cathepsin E CTSE 1q31 50.9 8.89 0.17
AI868227 Alcohol dehydrogenase 1C (class I), gamma polypeptide ADH1C 4q21 90.61 14.54 0.16
AA025150 Fructose-1,6-bisphosphatase 2 FBP2 9q22.3 8.26 1.28 0.15
R51912 Somatostatin SST 3q28 5.3 0.8 0.15
R91396 Annexin A10 ANXA10 4q33 54.38 7.9 0.15
AA977679 Somatostatin receptor 1 SSTR1 14q13 11.04 1.53 0.14
AA159577 Mucin 5AC, oligomeric mucus/gel-forming MUC5AC 11p15.5 68.25 9.44 0.14
AI611214 Est Est 19.87 2.58 0.13
AI074272 Calpain 9 CAPN9 1q42.11 10.33 1.34 0.13
AI652557 Aldehyde dehydrogenase 3 family, memberA1 ALDH3A1 17p11.2 2.29 0.26 0.11
AI074272 Calpain 9 CAPN9 1q42.11 30.5 3.28 0.11
AI538192 Major facilitator superfamily domain containing 4 MFSD4 1q32.1 14.8 1.57 0.11
AI002047 Poly (ADP-ribose) polymerase family, member 10 PARP10 8q24.3 14.86 1.43 0.1
H23187 Carbonic anhydrase II CA2 8q22 66.35 5.66 0.09
AI301329 Aldo-keto reductase family 1, member B10 AKR1B10 7q33 1.98 0.15 0.08
AI418194 SRY (sex determining region Y)-box 21 SOX21 13q31 16.61 1.25 0.08
AI924753 Aldo-keto reductase family 1, member B10 AKR1B10 7q33 2.29 0.17 0.07
AI863845 Alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide ADH7 4q23 16.46 0.97 0.06
AA844831 Carboxypeptidase A2 (pancreatic) CPA2 7q32 24.56 1.17 0.05
AI001183 Rab15 effector protein REP15 12p11.22 24.73 1.17 0.05
AI271987 FLJ42875 protein FLJ42875 1p36.32 29.28 1.32 0.05
AI913412 Estrogen-related receptor gamma ESRRG 1q41 19.93 0.87 0.04
AA976699 Chromogranin A (parathyroid secretory protein 1) CHGA 14q32 28.17 1.18 0.04
R72097 Pepsinogen 3, group I (pepsinogen A) PGA3 11q12.2 96.86 3.62 0.04
AI368486 Ghrelin/obestatin preprohormone GHRL 3p26 38.12 1.39 0.04
AW058221 Lipase, gastric LIPF 10q23.31 100 1.39 0.01
‘GB acc’ refers to the Genbank accession number. ‘N’ and ‘T’ refer to average gene expression ratios from normal (n=28) and tumor (n=28) samples in the training
set, respectively, and ‘T/N’ is the gene expression ratio in tumor tissues over normal tissues. The information on the gene names, gene symbols and cytoband
information was from SOURCE [23]. Ninety-two genes (probes) are those containing unique GB acc. Some genes have more than 2 GB acc. For example, there are 2
probes for Aldo-keto reductase family 1, member B10 (AKR1B10), Calpain 9 (CAPN9), Aldehyde dehydrogenase 3 family, memberA1 (ALDH3A1) and Thy-1 cell
surface antigen (THY1). The probe with accession number #AI611214 has been retracted from the public data base from the initial submission of this manuscript.
Therefore, this table represents information for 85 non-redundant genes.
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and average expression ratios in normal and tumor tissues, is
described in Table 2.
An identical sample labeled Y-GC-01-049 was incorrectly
predicted as a normal. Tissues, Y-GC-01-049 and Y-GC-01-
048, were originally given for the hybridization as a tumor
and a normal tissue, respectively, originated from one patient.
The reason for the incorrect prediction in the test set could
be due to either an imperfect prediction algorithm or a
technical mix-up during sample handling. Both of the Y-GC-
01-048 and Y-GC-01-049 were subjected to haematoxylin
and eosin (H&E) staining in order to clarify the ambiguity.
H&E staining confirmed that the Y-GC-01-048 is a normal
gastric tissue with gastritis. The Y-GC-01-049, which was
labeled as a tumor, but was predicted to be normal by
expression profiling-based prediction, was confirmed as a
normal (Fig. 2), showing that the class prediction algorithm
can correctly identify the tissue types based only on the gene
expression profiles. Based on this confirmation, the selected
gene set can function as a predictor gene set that can
successfully distinguish between normal and tumor tissues of
gastric cancer.3.2. Confirmation of the gene expression pattern by real-time
RT-PCR
We tested if the differential expression pattern of the predictor
genes could be recapitulated using real-time RT-PCR. For this 5
genes were selected from Table 1, including Pepsinogen 5
(PGA5), Lipase, gastric (LIPF), Thrombospondin 2 (THBS2),
Rab15 effector protein (REP15) and Poly (ADP-ribose)
polymerase family, member 10 (PARP10). The ratios of each
gene to control Actin beta were measured using total RNAs
from 3 normal tissues and 3 tumor tissues, which were also used
for gene expression profiling. The expression ratios of each
gene in 6 tissues measured by real time RT-PCR and microarray
experiments were then compared by way of Pearson's
correlation. Higher correlations (R2N0.9) between expression
ratios measured by microarray and RT-PCR over 6 tissues were
observed for PGA5, LIPF, THBS2 and REP15 (Fig. 3). A rather
low correlation was observed for PARP10. Excluding PARP10,
a combined analysis for expression ratios of 4 genes between
microarray and RT-PCR also resulted in high correlation
(R2=0.9199), while the presence of PARP10 in the combined
analysis led to R2 value of 0.69.
Fig. 2. Confirmation of gene expression-based prediction of the gastric tissue types by H&E staining. The tissue sample of YGC-01-049 was labeled as a tumor sample,
but was predicted as a normal gastric tissue. H&E staining together with YGC-01-048 confirms that the YGC-01-049 is a normal gastric tissue.
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normal and tumor tissues of gastric cancer
To interpret the function of the selected genes in a
biologically meaningful manner, the 92 genes were subjected
to pathway analysis. Five KEGG (Kyoto Encyclopedia of
Genes and Genomes) molecular pathways represent the
function of 92 genes. These include Thrombospondin 2
(THBS2), Platelet derived growth factor D (PDGFD),
Mitogen-activated protein kinase 1 (MAPK1), Collagen, type
I, alpha 2 (COL1A2), Collagen, type VI, alpha 3 (COL6A3)
of the ‘focal adhesion’ pathway that is involved in cell–cell
communication. The ‘ECM–receptor interaction’ pathway,
involved in the processing of the cell signaling, represents
THBS2, COL1A2, COL6A3 and Fibronectin 1 (FN1). The
‘TGF-beta signaling’ is one of the major signal transduction
pathways and contains THBS2, MAPK1 and Inhibin beta A
(INHBA) of the 92 genes. Two of the human disease
pathways, ‘colorectal cancer’ and ‘prion disease’, are collec-
tion of genes known to be involved in human diseases, and
represent PDGFD, MAPK1 and Nuclear factor (erythroid-
derived 2)-like 2 (NFE2L2), respectively, in the 92-gene set.
4. Discussion
Major efforts are being made to develop molecular signature-
based methods to complement the traditional histopathological
diagnosis in gastric cancer and also to understand gastric cancer
at a molecular level. Inoue et al. performed expression profiling
on gastric tissues from 43 patients to build a prognostic scoring
system that can aid in the understanding of the malignant
behavior of the gastric tumors [19]. Hasegawa et al. looked into
the intestinal-type gastric tissues obtained by laser-capturemicrodissection and identified genes differentially expressed in
intestinal-type cancer and in lymph node metastasis [20]. Hippo
et al. identified differential gene expression patterns between 22
gastric cancers and 8 non-cancerous tissues using oligonucleo-
tide microarrays containing 6800 genes [7]. In a larger scale
expression profiling, Boussioustas et al. identified genes
differentially expressed between histological subtypes of
tumors and pre-malignant gastric mucosa [8]. There also has
been a study to correlate genetic aberrations and gene
expression profiling [9], and Chen et al. identified genes
whose expression levels were significantly correlated with
patient survival [10].
Our study is distinguished from the previous studies in that a
relatively large number of samples and genes were used for the
expression profiling and class prediction algorithm is used in
the assessment of the selected genes. We focused our attention
in this study to the molecular differences between normal and
tumor phenotypes of gastric cancer. Supervised learning
classifications have been largely performed by the three
algorithms; weighted voting [11], k-nearest neighbors (k-NN)
[21] and support vector machine (SVM) [22]. We employed k-
NN classification algorithm as a prediction method in this
report. To eliminate the possibility that the current result is due
to a possible bias by an algorithm used in this specific case, we
also tried SVM as a prediction algorithm using 92 genes. The
same result as was observed in the SVM-based class prediction,
with the same tumor sample Y-GC-01-049 being incorrectly
predicted as a normal tissue in the test set. This suggests that the
current results are not due to a bias originating from the use of a
specific statistical algorithm.
Elucidating the molecular-level differences between normal
and tumor tissues, as we have done in this report, may not have
much clinical applicability. However, it is essential to the
Fig. 3. Confirmation of microarray data with real-time RT-PCR. (A) The correlations between expression ratios over 6 tissues measured by microarray (normalized
ratio) and real-time RT-PCR (beta Actin-normalized ratio) are shown individually for 5 genes. (B) A combined analysis of correlation between microarray and real-
time RT-PCR data for 5 genes including PARP10 or only 4 genes without PARP10.
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be useful in the development of therapeutic reagent in the long
run. The 92 genes, in Fig. 1 and detailed in Table 1, represent
diverse molecular functions including protease inhibitor, tumor
suppressor and transcription factors and represent molecular
pathways such as focal adhesion (THBS2, PDGFD, MAPK1,
COL1A2, COL6A3 and FN1), transforming growth factor-beta
(TGF-β) signaling (THBS2, MAPK1 and INHBA). These are
major molecular pathways influencing their effect on diverse
cellular processes including cell growth, cell differentiation and
cell death. To study some of the potential genes for their
biochemical roles in the development of gastric cancer, their
expression patterns in the gastric cancer cell lines need to be
examined. Currently gene expression profiling for the all the
available gastric cancer cells is underway. We used class
prediction algorithm as a way of selecting for the genes
differentially expressed between normal and tumor tissues from
gastric cancer. Prediction of the unknown samples was
performed to minimize the false positives, rather than for
diagnosis purposes. Clinically, diagnosis of normal and/or
tumor tissues originated from gastric cancer patients does not
require the massive expression profiling studies as we have
presented here. However, information on gene expression
changes between the two tissue groups would be essential to
understand this disease at a molecular level.
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